Figure 1.
Figure 1. Hemolytic anemia conditions encountered before, during and after hematopoietic stem cell transplantation (HSCT). *All RBC concentrates should be γ-irradiated (25-30 Gy) and leukocyte reduced. Consider HLA-alloimmunization. ¶See Table 3. AH indicates acute hemolysis; AIHA, autoimmune hemolytic anemia; BM, bone marrow; CB, cord blood; CBC, complete blood count; CLL, chronic lymphocytic leukemia; CVID, common variable immunodeficiency; D, donor; DAT, direct antiglobulin test; DIC, diffuse intravascular coagulation; DIHA, drug-induced HA; LDH, lactate dehydrogenase; PBSC, periphereal blood stem cells; PLS, passenger lymphocyte syndrome; Plt, platelets; PNH, paroxysmal nocturnal hemoglobinuria; PRCA, pure red cell aplasia; PTLD, post-transplant lymphoproliferative disease; R, recipient; Rc, reticulocytes; SAA, severe aplastic anemia; and TMA, thrombotic microangiopathy.

Hemolytic anemia conditions encountered before, during and after hematopoietic stem cell transplantation (HSCT). *All RBC concentrates should be γ-irradiated (25-30 Gy) and leukocyte reduced. Consider HLA-alloimmunization. See Table 3. AH indicates acute hemolysis; AIHA, autoimmune hemolytic anemia; BM, bone marrow; CB, cord blood; CBC, complete blood count; CLL, chronic lymphocytic leukemia; CVID, common variable immunodeficiency; D, donor; DAT, direct antiglobulin test; DIC, diffuse intravascular coagulation; DIHA, drug-induced HA; LDH, lactate dehydrogenase; PBSC, periphereal blood stem cells; PLS, passenger lymphocyte syndrome; Plt, platelets; PNH, paroxysmal nocturnal hemoglobinuria; PRCA, pure red cell aplasia; PTLD, post-transplant lymphoproliferative disease; R, recipient; Rc, reticulocytes; SAA, severe aplastic anemia; and TMA, thrombotic microangiopathy.

Close Modal

or Create an Account

Close Modal
Close Modal